Ingevity reports fourth quarter and full year 2024 financial results
Fourth Quarter:
-
Net sales of
decreased$298.8 million 20% compared to prior year primarily due to repositioning actions in the Performance Chemicals segment that resulted in the exit of lower-margin end markets -
Net income of
and diluted earnings per share (EPS) of$16.6 million , including pre-tax restructuring charges of$0.46 ; adjusted earnings of$23.4 million and diluted adjusted EPS of$34.7 million $0.95 -
Adjusted EBITDA of
and adjusted EBITDA margin of$80.6 million 27.0% -
Operating cash flow of
and free cash flow of$64.5 million , which included the second and final$39.6 million installment of a termination fee for a long-term crude tall oil (CTO) supply agreement$50.0 million
Full Year:
-
Net sales of
decreased$1.4 billion 17% compared to prior year primarily due to repositioning actions in the Performance Chemicals segment that resulted in the exit of lower-margin end markets -
Net loss of
and diluted loss per share of$430.3 million , including pre-tax charges of$11.85 primarily related to the Performance Chemicals segment; adjusted earnings of$688.0 million and diluted adjusted EPS of$128.3 million $3.51 -
Adjusted EBITDA of
and adjusted EBITDA margin of$362.7 million 25.8% -
Operating cash flow of
with free cash flow of$128.6 million $51.0 million - In January 2025, announced plans to explore strategic alternatives for Performance Chemicals Industrial Specialties product line and North Charleston CTO refinery
Guidance:
Company announces full year 2025 guidance of sales between
The results and guidance in this release include non-GAAP financial measures. Refer to the section entitled “Use of non-GAAP financial measures” within this release. All comparisons are made versus the same period in 2023 unless otherwise stated.
Fourth quarter (Q4) net sales of
Full year (FY) net sales of
“Ingevity’s management team and Board have taken aggressive actions to improve performance and our stronger than expected results are evidence of our solid execution,” said Luis Fernandez-Moreno, interim president and CEO. “We remain focused on our key priorities which are execution excellence, reducing leverage, and portfolio optimization to accelerate the delivery of shareholder value.”
Fernandez-Moreno continued, “Performance Materials had its best year yet, meeting the increased demand for more fuel-efficient vehicles that require the advanced solutions provided by our activated carbon. The segment achieved record sales and EBITDA due to increased volumes, improved price and mix and lower costs. Our focus on manufacturing efficiency was a key component to reduced costs and improved profitability which greatly contributed to the company’s solid free cash flow for the year. Advanced Polymer Technologies increased volumes despite continued weak industrial demand, but volume growth was more than offset by adverse mix and selective price concessions implemented to maintain share. 2024 was a transformational year for Performance Chemicals (PC) as we took major steps to reposition the segment, which resulted in significantly improved segment EBITDA margins in the second half. As part of the continued review of our portfolio of businesses, we recently announced plans to explore strategic alternatives for the Industrial Specialties product line and North Charleston CTO refinery. We believe this action will further strengthen the PC segment and enable us to focus our attention on higher growth and higher margin opportunities within our portfolio while improving the company’s earnings and cash flow.”
Performance Materials
Sales in Performance Materials were up
Advanced Polymer Technologies
Sales in the Advanced Polymer Technologies segment were
Performance Chemicals
Sales in the Performance Chemicals segment were
Liquidity/Other
Full year operating cash flow was
Full Year 2025 Guidance
Ingevity announced its 2025 guidance of sales between
“The actions we took in 2024 position the company to deliver more profitable growth in 2025 and beyond. We are committed to enhancing shareholder value through improved EBITDA with margins approaching
Additional Information
The company will host a live webcast on Wednesday, February 19, at 10:00 a.m. (Eastern) to discuss Ingevity’s fourth-quarter and full year 2024 fiscal results. The webcast can be accessed here or on the investors section of Ingevity’s website. You may also listen to the conference call by dialing 833 470 1428 (inside the
Ingevity: Purify, Protect and Enhance
Ingevity provides products and technologies that purify, protect and enhance the world around us. Through a team of talented and experienced people, we develop, manufacture and bring to market solutions that help customers solve complex problems and make the world more sustainable. We operate in three reporting segments: Performance Materials, which includes activated carbon; Advanced Polymer Technologies, which includes caprolactone polymers; and Performance Chemicals, which includes specialty chemicals and road technologies. Our products are used in a variety of demanding applications, including adhesives, agrochemicals, asphalt paving, certified biodegradable bioplastics, coatings, elastomers, pavement markings and automotive components. Headquartered in
Use of non-GAAP financial measures: This press release includes certain non‐GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. Reconciliations of non‐GAAP financial measures to GAAP financial measures are provided within the Appendix to this press release. Investors are urged to consider carefully the comparable GAAP measures and the reconciliations to those measures provided. The company does not attempt to provide reconciliations of forward-looking non-GAAP guidance to the comparable GAAP measure because the impact and timing of the factors underlying the guidance assumptions are inherently uncertain and difficult to predict and are unavailable without unreasonable efforts. In addition, Ingevity believes such reconciliations would imply a degree of certainty that could be confusing to investors.
Forward-looking statements: This press release contains “forward looking statements” within the meaning of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such statements generally include the words “will,” “plans,” “intends,” “targets,” “expects,” “outlook,” “guidance,” “believes,” “anticipates” or similar expressions. Forward looking statements may include, without limitation, anticipated timing, results, charges and costs of any current or future repositioning of our Performance Chemicals segment, including the announced review of strategic alternatives for the Industrial Specialties product line and
INGEVITY CORPORATION Condensed Consolidated Statements of Operations (Unaudited) |
|||||||||||||||
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
||||||||||||
In millions, except per share data |
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Net sales |
$ |
298.8 |
|
|
$ |
371.7 |
|
|
$ |
1,406.4 |
|
|
$ |
1,692.1 |
|
Cost of sales |
|
196.9 |
|
|
|
312.2 |
|
|
|
951.7 |
|
|
|
1,220.2 |
|
Gross profit |
|
101.9 |
|
|
|
59.5 |
|
|
|
454.7 |
|
|
|
471.9 |
|
Selling, general, and administrative expenses |
|
39.4 |
|
|
|
43.4 |
|
|
|
166.7 |
|
|
|
183.7 |
|
Research and technical expenses |
|
7.3 |
|
|
|
7.2 |
|
|
|
28.1 |
|
|
|
31.8 |
|
Restructuring and other (income) charges, net |
|
23.4 |
|
|
|
120.8 |
|
|
|
186.2 |
|
|
|
170.2 |
|
Goodwill impairment charge |
|
— |
|
|
|
— |
|
|
|
349.1 |
|
|
|
— |
|
Acquisition-related costs |
|
0.3 |
|
|
|
(0.2 |
) |
|
|
0.3 |
|
|
|
3.6 |
|
Other (income) expense, net |
|
1.9 |
|
|
|
19.6 |
|
|
|
169.8 |
|
|
|
5.7 |
|
Interest expense, net |
|
20.8 |
|
|
|
22.7 |
|
|
|
90.1 |
|
|
|
87.0 |
|
Income (loss) before income taxes |
|
8.8 |
|
|
|
(154.0 |
) |
|
|
(535.6 |
) |
|
|
(10.1 |
) |
Provision (benefit) for income taxes |
|
(7.8 |
) |
|
|
(37.2 |
) |
|
|
(105.3 |
) |
|
|
(4.7 |
) |
Net income (loss) |
$ |
16.6 |
|
|
$ |
(116.8 |
) |
|
$ |
(430.3 |
) |
|
$ |
(5.4 |
) |
|
|
|
|
|
|
|
|
||||||||
Per share data |
|
|
|
|
|
|
|
||||||||
Basic earnings (loss) per share |
$ |
0.46 |
|
|
$ |
(3.23 |
) |
|
$ |
(11.85 |
) |
|
$ |
(0.15 |
) |
Diluted earnings (loss) per share |
$ |
0.46 |
|
|
$ |
(3.23 |
) |
|
$ |
(11.85 |
) |
|
$ |
(0.15 |
) |
Weighted average shares outstanding |
|
|
|
|
|
|
|
||||||||
Basic |
|
36.3 |
|
|
|
36.2 |
|
|
|
36.3 |
|
|
|
36.5 |
|
Diluted |
|
36.6 |
|
|
|
36.2 |
|
|
|
36.3 |
|
|
|
36.5 |
|
INGEVITY CORPORATION Segment Operating Results (Unaudited) |
|||||||||||||||
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
||||||||||||
In millions |
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Net sales |
|
|
|
|
|
|
|
||||||||
Performance Materials |
$ |
156.2 |
|
|
$ |
152.8 |
|
|
$ |
609.6 |
|
|
$ |
586.0 |
|
Performance Chemicals |
|
98.7 |
|
|
|
176.5 |
|
|
|
608.2 |
|
|
|
902.1 |
|
Road Technologies product line |
|
48.5 |
|
|
|
53.4 |
|
|
|
342.3 |
|
|
|
369.8 |
|
Industrial Specialties product line |
|
50.2 |
|
|
|
123.1 |
|
|
|
265.9 |
|
|
|
532.3 |
|
Advanced Polymer Technologies |
|
43.9 |
|
|
|
42.4 |
|
|
|
188.6 |
|
|
|
204.0 |
|
Total net sales |
$ |
298.8 |
|
|
$ |
371.7 |
|
|
$ |
1,406.4 |
|
|
$ |
1,692.1 |
|
|
|
|
|
|
|
|
|
||||||||
Segment EBITDA (1) |
|
|
|
|
|
|
|
||||||||
Performance Materials |
$ |
78.3 |
|
|
$ |
78.1 |
|
|
$ |
319.1 |
|
|
$ |
286.6 |
|
Performance Chemicals |
|
(3.8 |
) |
|
|
(24.2 |
) |
|
|
14.7 |
|
|
|
65.7 |
|
Advanced Polymer Technologies |
|
6.1 |
|
|
|
7.9 |
|
|
|
35.2 |
|
|
|
44.5 |
|
Total segment EBITDA (1) |
$ |
80.6 |
|
|
$ |
61.8 |
|
|
$ |
369.0 |
|
|
$ |
396.8 |
|
|
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
(20.8 |
) |
|
|
(22.7 |
) |
|
|
(90.1 |
) |
|
|
(87.0 |
) |
(Provision) benefit for income taxes |
|
7.8 |
|
|
|
37.2 |
|
|
|
105.3 |
|
|
|
4.7 |
|
Depreciation and amortization (2) |
|
(25.2 |
) |
|
|
(30.7 |
) |
|
|
(108.3 |
) |
|
|
(122.8 |
) |
Restructuring and other income (charges), net (3)(4) |
|
(23.4 |
) |
|
|
(120.8 |
) |
|
|
(186.2 |
) |
|
|
(170.2 |
) |
Goodwill impairment charge (3)(5) |
|
— |
|
|
|
— |
|
|
|
(349.1 |
) |
|
|
— |
|
Acquisition and other-related costs (3)(5) |
|
(0.3 |
) |
|
|
0.1 |
|
|
|
(0.3 |
) |
|
|
(4.5 |
) |
Inventory charges (3)(6) |
|
— |
|
|
|
(19.7 |
) |
|
|
(6.3 |
) |
|
|
(19.7 |
) |
Loss on CTO resales (3)(5) |
|
(1.9 |
) |
|
|
(22.0 |
) |
|
|
(52.7 |
) |
|
|
(22.0 |
) |
CTO supply contract termination charges (3)(5) |
|
— |
|
|
|
— |
|
|
|
(100.0 |
) |
|
|
— |
|
Gain (loss) on sale of strategic investment (3)(7) |
|
— |
|
|
|
— |
|
|
|
(11.4 |
) |
|
|
19.3 |
|
Pension and postretirement settlement and curtailment (charges) income, net (3)(5) |
|
(0.2 |
) |
|
|
— |
|
|
|
(0.2 |
) |
|
|
— |
|
Net income (loss) |
$ |
16.6 |
|
|
$ |
(116.8 |
) |
|
$ |
(430.3 |
) |
|
$ |
(5.4 |
) |
_______________ | |
(1) |
Segment EBITDA is the primary measure used by our chief operating decision maker ("CODM"), the Interim CEO and President of Ingevity, to evaluate the performance of and allocate resources among our operating segments. Segment EBITDA is defined as segment net sales less segment operating expenses (segment operating expenses consist of costs of sales, selling, general and administrative expenses, research and technical expenses, other (income) expense, net, excluding depreciation and amortization). We have excluded the following items from segment EBITDA: interest expense associated with corporate debt facilities, interest income, income taxes, depreciation, amortization, goodwill impairment charge, restructuring and other income (charges), net, litigation verdict charges, inventory lower of cost or market charges associated with restructuring actions, acquisition and other-related income (costs), gain (loss) on sale of strategic investments, loss on CTO resales, CTO supply contract termination charges, and pension and postretirement settlement and curtailment income (charges), net. |
(2) |
The table below provides an allocation of these charges between our three reportable segments to provide investors, potential investors, securities analysts and others with the information, should they choose, to apply such charges to each respective reportable segment for which the charges relate. |
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
||||||||||||
In millions |
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Performance Materials |
$ |
(9.7 |
) |
|
$ |
(9.6 |
) |
|
$ |
(38.7 |
) |
|
$ |
(38.3 |
) |
Performance Chemicals |
|
(7.7 |
) |
|
|
(13.2 |
) |
|
|
(38.8 |
) |
|
|
(53.2 |
) |
Advanced Polymer Technologies |
|
(7.8 |
) |
|
|
(7.9 |
) |
|
|
(30.8 |
) |
|
|
(31.3 |
) |
Depreciation and amortization |
$ |
(25.2 |
) |
|
$ |
(30.7 |
) |
|
$ |
(108.3 |
) |
|
$ |
(122.8 |
) |
(3) |
For more information on these charges, refer to the Reconciliation of Adjusted Earnings table on page 7. |
(4) |
We regularly perform strategic reviews and assess the return on our operations, which sometimes results in a plan to restructure the business. These costs are excluded from our reportable segment results. The table below provides an allocation of these charges between our three reportable segments to provide investors, potential investors, securities analysts and others with the information, should they choose, to apply such (income) charges to each respective reportable segment for which the charges relate. |
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
||||||||||||
In millions |
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Performance Materials |
$ |
0.2 |
|
$ |
1.6 |
|
$ |
0.9 |
|
$ |
9.0 |
||||
Performance Chemicals |
|
23.1 |
|
|
104.8 |
|
|
185.1 |
|
|
144.5 |
||||
Advanced Polymer Technologies |
|
0.1 |
|
|
14.4 |
|
|
0.2 |
|
|
16.7 |
||||
Restructuring and other (income) charges, net |
$ |
23.4 |
|
$ |
120.8 |
|
$ |
186.2 |
|
$ |
170.2 |
(5) |
For all periods presented, charges relate to the Performance Chemicals reportable segment. |
(6) |
For all periods presented, inventory charges represent lower of cost or market charges associated with the Performance Chemicals’ repositioning. These charges were not allocated in the measurement of our Performance Chemicals reportable segment profitability used by our CODM. Amounts are included in Cost of sales on the consolidated statement of operations. |
(7) |
The table below provides an allocation of these charges between our three reportable segments to provide investors, potential investors, securities analysts and others with the information, should they choose, to apply such (income) charges to each respective reportable segment for which the charges relate. |
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
||||||||||||
In millions |
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Performance Materials |
$ |
— |
|
$ |
— |
|
$ |
(0.1 |
) |
|
$ |
(19.3 |
) |
||
Performance Chemicals |
|
— |
|
|
— |
|
|
9.3 |
|
|
|
— |
|
||
Advanced Polymer Technologies |
|
— |
|
|
— |
|
|
2.2 |
|
|
|
— |
|
||
(Gain) loss on sale of strategic investment |
$ |
— |
|
$ |
— |
|
$ |
11.4 |
|
|
$ |
(19.3 |
) |
INGEVITY CORPORATION Condensed Consolidated Balance Sheets (Unaudited) |
|||||
|
December 31, |
||||
In millions |
2024 |
|
2023 |
||
Assets |
|
|
|
||
Cash and cash equivalents |
$ |
68.0 |
|
$ |
95.9 |
Accounts receivable, net |
|
141.0 |
|
|
182.0 |
Inventories, net |
|
226.8 |
|
|
308.8 |
Prepaid and other current assets |
|
57.4 |
|
|
71.9 |
Current assets |
|
493.2 |
|
|
658.6 |
Property, plant, and equipment, net |
|
658.9 |
|
|
762.2 |
Goodwill |
|
175.2 |
|
|
527.5 |
Other intangibles, net |
|
278.8 |
|
|
336.1 |
Restricted investment |
|
81.6 |
|
|
79.1 |
Strategic investments |
|
87.3 |
|
|
99.2 |
Other assets |
|
247.6 |
|
|
160.6 |
Total Assets |
$ |
2,022.6 |
|
$ |
2,623.3 |
|
|
|
|
||
Liabilities |
|
|
|
||
Accounts payable |
$ |
94.5 |
|
$ |
158.4 |
Accrued expenses |
|
58.1 |
|
|
72.3 |
Notes payable and current maturities of long-term debt |
|
61.3 |
|
|
84.4 |
Other current liabilities |
|
50.2 |
|
|
47.8 |
Current liabilities |
|
264.1 |
|
|
362.9 |
Long-term debt including finance lease obligations |
|
1,339.7 |
|
|
1,382.8 |
Deferred income taxes |
|
56.2 |
|
|
70.9 |
Other liabilities |
|
167.4 |
|
|
175.3 |
Total Liabilities |
|
1,827.4 |
|
|
1,991.9 |
Equity |
|
195.2 |
|
|
631.4 |
Total Liabilities and Equity |
$ |
2,022.6 |
|
$ |
2,623.3 |
INGEVITY CORPORATION Condensed Consolidated Statements of Cash Flows (Unaudited) |
|||||||||||||||
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
||||||||||||
In millions |
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Cash provided by (used in) operating activities: |
|
|
|
|
|
|
|
||||||||
Net income (loss) |
$ |
16.6 |
|
|
$ |
(116.8 |
) |
|
$ |
(430.3 |
) |
|
$ |
(5.4 |
) |
Adjustments to reconcile net income (loss) to cash provided by operating activities: |
|
|
|
|
|
|
|
||||||||
Depreciation and amortization |
|
25.2 |
|
|
|
30.7 |
|
|
|
108.3 |
|
|
|
122.8 |
|
(Gain) loss on strategic investment |
|
— |
|
|
|
— |
|
|
|
11.4 |
|
|
|
(19.3 |
) |
CTO resales |
|
1.9 |
|
|
|
22.0 |
|
|
|
52.7 |
|
|
|
22.0 |
|
Goodwill impairment charge |
|
— |
|
|
|
— |
|
|
|
349.1 |
|
|
|
— |
|
Restructuring and other (income) charges, net |
|
23.4 |
|
|
|
120.8 |
|
|
|
186.2 |
|
|
|
170.2 |
|
Other non-cash items |
|
(100.8 |
) |
|
|
(15.9 |
) |
|
|
(89.3 |
) |
|
|
99.5 |
|
Changes in operating assets and liabilities, net of effect of acquisitions: |
|
|
|
|
|
|
|
||||||||
Restructuring and other spending |
|
(15.4 |
) |
|
|
(12.8 |
) |
|
|
(59.3 |
) |
|
|
(44.0 |
) |
CTO Resales |
|
(1.1 |
) |
|
|
(10.6 |
) |
|
|
(46.1 |
) |
|
|
(10.6 |
) |
Changes in other operating assets and liabilities, net |
|
114.7 |
|
|
|
27.0 |
|
|
|
45.9 |
|
|
|
(130.1 |
) |
Net cash provided by (used in) operating activities |
$ |
64.5 |
|
|
$ |
44.4 |
|
|
$ |
128.6 |
|
|
$ |
205.1 |
|
Cash provided by (used in) investing activities: |
|
|
|
|
|
|
|
||||||||
Capital expenditures |
$ |
(24.9 |
) |
|
$ |
(29.2 |
) |
|
$ |
(77.6 |
) |
|
$ |
(109.8 |
) |
Proceeds from sale of strategic investment |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
31.5 |
|
Purchase of strategic investments |
|
(0.3 |
) |
|
|
— |
|
|
|
(0.3 |
) |
|
|
(2.4 |
) |
Other investing activities, net |
|
(2.8 |
) |
|
|
4.5 |
|
|
|
(1.6 |
) |
|
|
3.4 |
|
Net cash provided by (used in) investing activities |
$ |
(28.0 |
) |
|
$ |
(24.7 |
) |
|
$ |
(79.5 |
) |
|
$ |
(77.3 |
) |
Cash provided by (used in) financing activities: |
|
|
|
|
|
|
|
||||||||
Proceeds from revolving credit facility and other borrowings |
$ |
81.1 |
|
|
$ |
136.8 |
|
|
$ |
404.5 |
|
|
$ |
376.3 |
|
Payments on revolving credit facility |
|
(178.4 |
) |
|
|
(142.8 |
) |
|
|
(470.6 |
) |
|
|
(382.9 |
) |
Debt issuance costs |
|
— |
|
|
|
(0.4 |
) |
|
|
— |
|
|
|
(0.4 |
) |
Financing lease obligations, net |
|
(0.1 |
) |
|
|
(0.1 |
) |
|
|
(1.0 |
) |
|
|
(0.7 |
) |
Tax payments related to withholdings on vested equity awards |
|
(0.2 |
) |
|
|
— |
|
|
|
(3.1 |
) |
|
|
(4.8 |
) |
Proceeds and withholdings from share-based compensation plans, net |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
4.7 |
|
Repurchases of common stock under publicly announced plan |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(92.1 |
) |
Net cash provided by (used in) financing activities |
$ |
(97.6 |
) |
|
$ |
(6.5 |
) |
|
$ |
(70.2 |
) |
|
$ |
(99.9 |
) |
Increase (decrease) in cash, cash equivalents, and restricted cash |
|
(61.1 |
) |
|
|
13.2 |
|
|
|
(21.1 |
) |
|
|
27.9 |
|
Effect of exchange rate changes on cash |
|
(5.8 |
) |
|
|
2.7 |
|
|
|
(4.2 |
) |
|
|
(0.3 |
) |
Change in cash, cash equivalents, and restricted cash |
|
(66.9 |
) |
|
|
15.9 |
|
|
|
(25.3 |
) |
|
|
27.6 |
|
Cash, cash equivalents, and restricted cash at beginning of period |
|
153.5 |
|
|
|
96.0 |
|
|
|
111.9 |
|
|
|
84.3 |
|
Cash, cash equivalents, and restricted cash at end of period (1) |
$ |
86.6 |
|
|
$ |
111.9 |
|
|
$ |
86.6 |
|
|
$ |
111.9 |
|
|
|
|
|
|
|
|
|
||||||||
(1) Includes restricted cash of |
|||||||||||||||
|
|
|
|
|
|
|
|
||||||||
Supplemental cash flow information: |
|
|
|
|
|
|
|
||||||||
Cash paid for interest, net of capitalized interest |
$ |
24.4 |
|
|
$ |
24.8 |
|
|
$ |
85.4 |
|
|
$ |
82.7 |
|
Cash paid for income taxes, net of refunds |
|
2.9 |
|
|
|
1.8 |
|
|
|
26.9 |
|
|
|
29.7 |
|
Purchases of property, plant and equipment in accounts payable |
|
0.2 |
|
|
|
(3.3 |
) |
|
|
2.4 |
|
|
|
2.8 |
|
Leased assets obtained in exchange for new finance lease liabilities |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
0.2 |
|
Leased assets obtained in exchange for new operating lease liabilities |
|
0.5 |
|
|
|
3.1 |
|
|
|
6.0 |
|
|
|
29.1 |
|
Ingevity Corporation
Non-GAAP Financial Measures
Ingevity has presented certain financial measures, defined below, which have not been prepared in accordance with
We believe these non-GAAP financial measures provide management as well as investors, potential investors, securities analysts, and others with useful information to evaluate the performance of the business, because such measures, when viewed together with our financial results computed in accordance with GAAP, provide a more complete understanding of the factors and trends affecting our historical financial performance, liquidity measures, and projected future results.
Ingevity uses the following non-GAAP measures:
Adjusted earnings (loss) is defined as net income (loss) plus restructuring and other (income) charges, net, goodwill impairment charge, acquisition and other-related (income) costs, pension and postretirement settlement and curtailment (income) charges, loss on CTO resales, CTO supply contract termination charges, (gain) loss on strategic investments, debt refinancing fees, litigation verdict charges, and the income tax expense (benefit) on those items, less the provision (benefit) from certain discrete tax items.
Diluted adjusted earnings (loss) per share is defined as diluted earnings (loss) per common share plus restructuring and other (income) charges, net, per share, goodwill impairment charge per share, acquisition and other-related (income) costs per share, pension and postretirement settlement and curtailment (income) charges per share, loss on CTO resales per share, CTO supply contract termination charges per share, (gain) loss on strategic investments per share, debt refinancing fees per share, litigation verdict charge per share, and the income tax expense (benefit) per share on those items, less the provision (benefit) from certain discrete tax items per share.
Adjusted EBITDA is defined as net income (loss) plus interest expense, net, provision (benefit) for income taxes, depreciation, amortization, restructuring and other (income) charges, net, goodwill impairment charge, acquisition and other-related (income) costs, litigation verdict charges, (gain) loss on strategic investments, loss on CTO resales, CTO supply contract termination charges, and pension and postretirement settlement and curtailment (income) charges, net.
Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Net sales.
Free Cash Flow is defined as the sum of net cash provided by (used in) the following items: operating activities less capital expenditures.
Net Debt is defined as the sum of notes payable, short-term debt, current maturities of long-term debt and long-term debt including finance lease obligations less the sum of cash and cash equivalents, restricted cash associated with our new market tax credit financing arrangement, and restricted investment associated with certain finance lease obligations, excluding the allowance for credit losses on held-to-maturity debt securities held within the restricted investment.
Net Debt Ratio is defined as Net Debt divided by the last twelve months Adjusted EBITDA, inclusive of acquisition-related pro forma adjustments.
Ingevity's management also uses the above financial measures as the primary measures of profitability and liquidity of the business. In addition, Ingevity believes Adjusted EBITDA and Adjusted EBITDA Margin are useful measures because they exclude the effects of financing and investment activities as well as non-operating activities.
GAAP Reconciliation of 2025 Adjusted EBITDA Guidance
A reconciliation of net income to adjusted EBITDA as projected for 2025 is not provided. Ingevity does not forecast net income as it cannot, without unreasonable effort, estimate or predict with certainty various components of net income. These components, net of tax, include further restructuring and other income (charges), net; additional acquisition and other-related (income) costs; litigation verdict charges; additional pension and postretirement settlement and curtailment (income) charges; and revisions due to legislative tax rate changes. Additionally, discrete tax items could drive variability in our projected effective tax rate. All of these components could significantly impact such financial measures. Further, in the future, other items with similar characteristics to those currently included in adjusted EBITDA, that have a similar impact on the comparability of periods, and which are not known at this time, may exist and impact adjusted EBITDA.
INGEVITY CORPORATION
Reconciliation of Non-GAAP Financial Measures
Reconciliation of Net Income (Loss) (GAAP) to Adjusted Earnings (Loss) (Non-GAAP) and Reconciliation of Diluted Earnings (Loss) per Common Share (GAAP) to Diluted Adjusted Earnings per Share (Non-GAAP) |
|||||||||||||||
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
||||||||||||
In millions, except per share data (unaudited) |
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Net income (loss) (GAAP) |
$ |
16.6 |
|
|
$ |
(116.8 |
) |
|
$ |
(430.3 |
) |
|
$ |
(5.4 |
) |
Restructuring and other (income) charges, net (1) |
|
23.4 |
|
|
|
120.8 |
|
|
|
186.2 |
|
|
|
170.2 |
|
Goodwill impairment charge (2) |
|
— |
|
|
|
— |
|
|
|
349.1 |
|
|
|
— |
|
Acquisition and other-related costs (3) |
|
0.3 |
|
|
|
(0.1 |
) |
|
|
0.3 |
|
|
|
4.5 |
|
Loss on CTO resales (4) |
|
1.9 |
|
|
|
22.0 |
|
|
|
52.7 |
|
|
|
22.0 |
|
CTO supply contract termination charges (5) |
|
— |
|
|
|
— |
|
|
|
100.0 |
|
|
|
— |
|
(Gain) loss on sale of strategic investment (6) |
|
— |
|
|
|
— |
|
|
|
11.4 |
|
|
|
(19.3 |
) |
Pension and postretirement settlement and curtailment income (charges), net (7) |
|
0.2 |
|
|
|
— |
|
|
|
0.2 |
|
|
|
— |
|
Tax effect on items above (8) |
|
(7.7 |
) |
|
|
(33.6 |
) |
|
|
(165.7 |
) |
|
|
(41.8 |
) |
Certain discrete tax provision (benefit) (9) |
|
— |
|
|
|
0.5 |
|
|
|
24.4 |
|
|
|
(0.6 |
) |
Adjusted earnings (loss) (Non-GAAP) |
$ |
34.7 |
|
|
$ |
(7.2 |
) |
|
$ |
128.3 |
|
|
$ |
129.6 |
|
|
|
|
|
|
|
|
|
||||||||
Diluted earnings (loss) per common share (GAAP) |
$ |
0.46 |
|
|
$ |
(3.23 |
) |
|
$ |
(11.85 |
) |
|
$ |
(0.15 |
) |
Restructuring and other (income) charges |
|
0.64 |
|
|
|
3.34 |
|
|
|
5.12 |
|
|
|
4.64 |
|
Goodwill impairment charge |
|
— |
|
|
|
— |
|
|
|
9.62 |
|
|
|
— |
|
Acquisition and other-related costs |
|
0.01 |
|
|
|
— |
|
|
|
0.01 |
|
|
|
0.12 |
|
Loss on CTO resales |
|
0.05 |
|
|
|
0.61 |
|
|
|
1.45 |
|
|
|
0.60 |
|
CTO supply contract termination charges |
|
— |
|
|
|
— |
|
|
|
2.75 |
|
|
|
— |
|
(Gain) loss on sale of strategic investment |
|
— |
|
|
|
— |
|
|
|
0.31 |
|
|
|
(0.52 |
) |
Pension and postretirement settlement and curtailment income (charges), net |
|
0.01 |
|
|
|
— |
|
|
|
0.01 |
|
|
|
— |
|
Tax effect on items above |
|
(0.22 |
) |
|
|
(0.93 |
) |
|
|
(4.58 |
) |
|
|
(1.14 |
) |
Certain discrete tax provision (benefit) |
|
— |
|
|
|
0.01 |
|
|
|
0.67 |
|
|
|
(0.02 |
) |
Diluted adjusted earnings (loss) per share (Non-GAAP) |
$ |
0.95 |
|
|
$ |
(0.20 |
) |
|
$ |
3.51 |
|
|
$ |
3.53 |
|
|
|
|
|
|
|
|
|
||||||||
Weighted average common shares outstanding - Diluted (10) |
|
36.6 |
|
|
|
36.2 |
|
|
|
36.5 |
|
|
|
36.7 |
|
___________ | |
(1) |
We regularly perform strategic reviews and assess the return on our operations, which sometimes results in a plan to restructure the business. These costs are excluded from our reportable segment results; details of which are included in the table below. For the details of these costs between our reportable segments, see Segment Operating Results on page 2. |
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
||||||||||||
In millions |
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Work force reductions and other |
$ |
2.3 |
|
$ |
0.9 |
|
$ |
2.3 |
|
$ |
12.5 |
||||
Performance Chemicals' repositioning |
|
14.8 |
|
|
113.1 |
|
|
172.7 |
|
|
113.1 |
||||
Restructuring charges (1) |
$ |
17.1 |
|
$ |
114.0 |
|
$ |
175.0 |
|
$ |
125.6 |
||||
Alternative feedstock transition |
|
— |
|
|
3.7 |
|
|
— |
|
|
22.1 |
||||
|
|
6.3 |
|
|
2.1 |
|
|
11.2 |
|
|
14.8 |
||||
Business transformation costs |
|
— |
|
|
1.0 |
|
|
— |
|
|
7.7 |
||||
Other (income) charges, net (1) |
$ |
6.3 |
|
$ |
6.8 |
|
$ |
11.2 |
|
$ |
44.6 |
||||
Restructuring and other (income) charges, net (2) |
$ |
23.4 |
|
$ |
120.8 |
|
$ |
186.2 |
|
$ |
170.2 |
||||
_________________ |
|||||||||||||||
(1) Amounts are recorded within Restructuring and other (income) charges, net on the condensed consolidated statement of operations. |
|||||||||||||||
(2) For information on our Workforce reductions and other, Performance Chemicals' repositioning, Alternative feedstock transition, |
(2) |
During the second quarter of 2024, the company concluded that the carrying amount of the Performance Chemicals reporting unit exceeded its fair value, resulting in a non-cash goodwill impairment charge. |
(3) |
Charges represent (gains) losses incurred to complete and integrate acquisitions and other strategic investments. Charges may include the expensing of the inventory fair value step-up resulting from the application of purchase accounting for acquisitions and certain legal and professional fees associated with the completion of acquisitions and strategic investments. For the details of these costs between our reportable segments, see Segment Operating Results on page 2. |
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
||||||||||||
In millions |
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Legal and professional service fees |
$ |
0.3 |
|
$ |
(0.2 |
) |
|
$ |
0.3 |
|
$ |
3.6 |
|||
Acquisition-related (income) costs |
$ |
0.3 |
|
$ |
(0.2 |
) |
|
$ |
0.3 |
|
$ |
3.6 |
|||
Inventory fair value step-up amortization (1) |
|
— |
|
|
0.1 |
|
|
|
— |
|
|
0.9 |
|||
Acquisition and other-related (income) charges |
$ |
0.3 |
|
$ |
(0.1 |
) |
|
$ |
0.3 |
|
$ |
4.5 |
|||
_________________ |
|||||||||||||||
(1) Included in Cost of sales on the condensed consolidated statement of operations. |
(4) |
Due to the DeRidder Plant closure and the corresponding reduced CTO refining capacity, we were obligated, under an existing CTO supply contract, to purchase CTO through 2025 at amounts in excess of required CTO volumes. As of July 1, 2024, we have terminated the CTO supply contract that resulted in these excess CTO volumes. As a result of the termination, the purchases under the CTO supply contract ended effective June 30, 2024. The CTO resale activity described above ended in 2024 and no excess CTO volumes were on hand at December 31, 2024. |
(5) |
As consideration for the termination of the CTO supply contract, we made a cash payment in the amount of |
(6) |
We exclude gains and losses from sales of strategic investments from our segment results, as well as our non-GAAP financial measures, because we do not consider such gains or losses to be directly associated with the operational performance of the segment. We believe that the inclusion of such gains or losses, would impair the factors and trends affecting the historical financial performance of our reportable segments. We continue to include undistributed earnings or loss, distributions, amortization or accretion of basis differences, and other-than-temporary impairments for equity method investments that we believe are directly attributable to the operational performance of such investments, in our reportable segment results. |
(7) |
Our pension and postretirement settlement and curtailment charges (income) are related to the acceleration of prior service costs, as a result of a reduction in the number of participants within the Union Hourly defined benefit pension plan. These are excluded from our segment results because we consider these costs to be outside our operational performance. We continue to include the service cost, amortization of prior service cost, interest costs, expected return on plan assets, and amortized actual gains and losses in our segment EBITDA. |
(8) |
Income tax impact of non-GAAP adjustments is the summation of the calculated income tax charge related to each pre-tax non-GAAP adjustment. The non-GAAP adjustments relate primarily to adjustments in |
(9) |
Represents certain discrete tax items such as excess tax benefits on stock compensation and impacts of legislative tax rate changes. |
(10) |
The weighted average number of shares outstanding used in diluted adjusted earnings per share computation (Non-GAAP) includes an average of 0.2 million diluted shares for the twelve months ended December 31, 2024 and 2023, respectively. This number of shares differs from the weighted average number of shares outstanding used in diluted loss per share computations (GAAP) as we had a net loss for each of those periods, respectively. |
Reconciliation of Net Income (Loss) (GAAP) to Adjusted Earnings (Loss) (Non-GAAP) and
Reconciliation of Diluted Earnings (Loss) per Common Share (GAAP) to
Diluted Adjusted Earnings per Share (Non-GAAP)
We revised our December 31, 2023 non-GAAP Adjusted earnings (loss) calculation to remove previous adjustments of
|
Three Months Ended
|
|
Twelve Months Ended
|
||||||||||||
In millions, except per share data (unaudited) |
As previously reported |
|
As revised |
|
As previously reported |
|
As revised |
||||||||
Net income (loss) (GAAP) |
$ |
(116.8 |
) |
|
$ |
(116.8 |
) |
|
$ |
(5.4 |
) |
|
$ |
(5.4 |
) |
Restructuring and other (income) charges, net (1) |
|
140.5 |
|
|
|
120.8 |
|
|
|
189.9 |
|
|
|
170.2 |
|
Acquisition and other-related costs (1) |
|
(0.1 |
) |
|
|
(0.1 |
) |
|
|
4.5 |
|
|
|
4.5 |
|
Loss on CTO resales (1) |
|
22.0 |
|
|
|
22.0 |
|
|
|
22.0 |
|
|
|
22.0 |
|
Gain on sale of strategic investment (1) |
|
— |
|
|
|
— |
|
|
|
(19.3 |
) |
|
|
(19.3 |
) |
Tax effect on items above (1) |
|
(38.3 |
) |
|
|
(33.6 |
) |
|
|
(46.4 |
) |
|
|
(41.8 |
) |
Certain discrete tax provision (benefit) (1) |
|
0.5 |
|
|
|
0.5 |
|
|
|
(0.6 |
) |
|
|
(0.6 |
) |
Adjusted earnings (loss) (Non-GAAP) |
$ |
7.8 |
|
|
$ |
(7.2 |
) |
|
$ |
144.7 |
|
|
$ |
129.6 |
|
|
|
|
|
|
|
|
|
||||||||
Diluted earnings (loss) per common share (GAAP) |
$ |
(3.23 |
) |
|
$ |
(3.23 |
) |
|
$ |
(0.15 |
) |
|
$ |
(0.15 |
) |
Restructuring and other (income) charges |
|
3.86 |
|
|
|
3.34 |
|
|
|
5.17 |
|
|
|
4.64 |
|
Acquisition and other-related costs |
|
— |
|
|
|
— |
|
|
|
0.12 |
|
|
|
0.12 |
|
Loss on CTO resales |
|
0.61 |
|
|
|
0.61 |
|
|
|
0.60 |
|
|
|
0.60 |
|
Gain on sale of strategic investment |
|
— |
|
|
|
— |
|
|
|
(0.52 |
) |
|
|
(0.52 |
) |
Tax effect on items above |
|
(1.04 |
) |
|
|
(0.93 |
) |
|
|
(1.26 |
) |
|
|
(1.14 |
) |
Certain discrete tax provision (benefit) |
|
0.01 |
|
|
|
0.01 |
|
|
|
(0.02 |
) |
|
|
(0.02 |
) |
Diluted adjusted earnings (loss) per share (Non-GAAP) |
$ |
0.21 |
|
|
$ |
(0.20 |
) |
|
$ |
3.94 |
|
|
$ |
3.53 |
|
|
|
|
|
|
|
|
|
||||||||
Weighted average common shares outstanding - Diluted |
|
36.4 |
|
|
|
36.2 |
|
|
|
36.7 |
|
|
|
36.7 |
|
___________ | |
(1) |
For more information on these charges, refer to the Reconciliation of Adjusted Earnings included in the Company’s Form 8-K for the year ended December 31, 2023, filed on February 21, 2024. |
Reconciliation of Net Income (Loss) (GAAP) to Adjusted EBITDA (Non-GAAP) |
|||||||||||||||
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
||||||||||||
In millions, except percentages (unaudited) |
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Net income (loss) (GAAP) |
$ |
16.6 |
|
|
$ |
(116.8 |
) |
|
$ |
(430.3 |
) |
|
$ |
(5.4 |
) |
Interest expense, net |
|
20.8 |
|
|
|
22.7 |
|
|
|
90.1 |
|
|
|
87.0 |
|
Provision (benefit) for income taxes |
|
(7.8 |
) |
|
|
(37.2 |
) |
|
|
(105.3 |
) |
|
|
(4.7 |
) |
Depreciation and amortization |
|
25.2 |
|
|
|
30.7 |
|
|
|
108.3 |
|
|
|
122.8 |
|
Restructuring and other (income) charges, net (1) |
|
23.4 |
|
|
|
120.8 |
|
|
|
186.2 |
|
|
|
170.2 |
|
Goodwill impairment charge (1) |
|
— |
|
|
|
— |
|
|
|
349.1 |
|
|
|
— |
|
Acquisition and other-related (income) costs (1) |
|
0.3 |
|
|
|
(0.1 |
) |
|
|
0.3 |
|
|
|
4.5 |
|
Loss on CTO resales (1) |
|
1.9 |
|
|
|
22.0 |
|
|
|
52.7 |
|
|
|
22.0 |
|
CTO supply contract termination charges (1) |
|
— |
|
|
|
— |
|
|
|
100.0 |
|
|
|
— |
|
(Gain) loss on sale of strategic investments (1) |
|
— |
|
|
|
— |
|
|
|
11.4 |
|
|
|
(19.3 |
) |
Pension and postretirement settlement and curtailment charges (income) (1) |
|
0.2 |
|
|
|
— |
|
|
|
0.2 |
|
|
|
— |
|
Adjusted EBITDA (Non-GAAP) |
$ |
80.6 |
|
|
$ |
42.1 |
|
|
$ |
362.7 |
|
|
$ |
377.1 |
|
|
|
|
|
|
|
|
|
||||||||
Net sales |
$ |
298.8 |
|
|
$ |
371.7 |
|
|
$ |
1,406.4 |
|
|
$ |
1,692.1 |
|
Net income (loss) margin |
|
5.6 |
% |
|
|
(31.4 |
)% |
|
|
(30.6 |
)% |
|
|
(0.3 |
)% |
Adjusted EBITDA margin |
|
27.0 |
% |
|
|
11.3 |
% |
|
|
25.8 |
% |
|
|
22.3 |
% |
___________ | |
(1) |
For more information on these charges, refer to the Reconciliation of Adjusted Earnings table on page 7. |
Reconciliation of Net Income (Loss) (GAAP) to Adjusted EBITDA (Non-GAAP)
We revised our December 31, 2023 non-GAAP Adjusted EBITDA calculation to remove previous adjustments of
|
Three Months Ended
|
|
Twelve Months Ended
|
||||||||||||
In millions, except percentages (unaudited) |
As previously reported |
|
As revised |
|
As previously reported |
|
As revised |
||||||||
Net income (loss) (GAAP) |
$ |
(116.8 |
) |
|
$ |
(116.8 |
) |
|
$ |
(5.4 |
) |
|
$ |
(5.4 |
) |
Provision (benefit) for income taxes |
|
22.7 |
|
|
|
22.7 |
|
|
|
87.0 |
|
|
|
87.0 |
|
Interest expense, net |
|
(37.2 |
) |
|
|
(37.2 |
) |
|
|
(4.7 |
) |
|
|
(4.7 |
) |
Depreciation and amortization |
|
30.7 |
|
|
|
30.7 |
|
|
|
122.8 |
|
|
|
122.8 |
|
Restructuring and other (income) charges, net (1) |
|
140.5 |
|
|
|
120.8 |
|
|
|
189.9 |
|
|
|
170.2 |
|
Acquisition and other-related (income) costs (1) |
|
(0.1 |
) |
|
|
(0.1 |
) |
|
|
4.5 |
|
|
|
4.5 |
|
Loss on CTO resales (1) |
|
22.0 |
|
|
|
22.0 |
|
|
|
22.0 |
|
|
|
22.0 |
|
(Gain) loss on strategic investments (1) |
|
— |
|
|
|
— |
|
|
|
(19.3 |
) |
|
|
(19.3 |
) |
Adjusted EBITDA (Non-GAAP) |
$ |
61.8 |
|
|
$ |
42.1 |
|
|
$ |
396.8 |
|
|
$ |
377.1 |
|
|
|
|
|
|
|
|
|
||||||||
Net sales |
$ |
371.7 |
|
|
$ |
371.7 |
|
|
$ |
1,692.1 |
|
|
$ |
1,692.1 |
|
Net income (loss) margin |
|
(31.4 |
)% |
|
|
(31.4 |
)% |
|
|
(0.3 |
)% |
|
|
(0.3 |
)% |
Adjusted EBITDA margin |
|
16.6 |
% |
|
|
11.3 |
% |
|
|
23.5 |
% |
|
|
22.3 |
% |
___________ | |
(1) |
For more information on these charges, refer to the Reconciliation of Adjusted Earnings included in the Company’s Form 8-K for the year ended December 31, 2023, filed on February 21, 2024. |
Calculation of Free Cash Flow (Non-GAAP) |
|||||||||||||||
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
||||||||||||
In millions (unaudited) |
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Net cash provided by (used in) operating activities |
$ |
64.5 |
|
$ |
44.4 |
|
$ |
128.6 |
|
$ |
205.1 |
||||
Less: Capital expenditures |
|
24.9 |
|
|
29.2 |
|
|
77.6 |
|
|
109.8 |
||||
Free Cash Flow (Non-GAAP) |
$ |
39.6 |
|
$ |
15.2 |
|
$ |
51.0 |
|
$ |
95.3 |
Calculation of Net Debt Ratio (Non-GAAP) |
|||
In millions, except ratios (unaudited) |
December 31, 2024 |
||
Notes payable and current maturities of long-term debt |
$ |
61.3 |
|
Long-term debt including finance lease obligations |
|
1,339.7 |
|
Debt issuance costs |
|
4.2 |
|
Total Debt |
|
1,405.2 |
|
Less: |
|
||
Cash and cash equivalents (1) |
|
68.2 |
|
Restricted investment (2) |
|
81.8 |
|
Net Debt |
$ |
1,255.2 |
|
|
|
||
Net Debt Ratio (Non-GAAP) |
|
||
Adjusted EBITDA (Non-GAAP) (3) |
|
||
Adjusted EBITDA - last twelve months (LTM) as of December 31, 2024 |
$ |
362.7 |
|
|
|
||
Net debt ratio (Non-GAAP) |
3.5x |
_______________ | |
(1) |
Includes |
(2) |
Our restricted investment is a trust managed in order to secure repayment of the finance lease obligation associated with Performance Materials' |
(3) |
Refer to the Reconciliation of Net Income (GAAP) to Adjusted EBITDA (Non-GAAP) schedule for the reconciliation to the most comparable GAAP financial measure. |
Calculation of Net Debt Ratio (Non-GAAP)
We revised our December 31, 2023 non-GAAP Net debt ratio calculation to remove the previous adjustment of
|
December 31, 2023 |
||||||
In millions, except ratios (unaudited) |
As previously reported |
|
As revised |
||||
Notes payable and current maturities of long-term debt |
$ |
84.4 |
|
$ |
84.4 |
||
Long-term debt including finance lease obligations |
|
1,382.8 |
|
|
1,382.8 |
||
Debt issuance costs |
|
5.3 |
|
|
5.3 |
||
Total Debt |
|
1,472.5 |
|
|
1,472.5 |
||
Less: |
|
|
|
||||
Cash and cash equivalents (1) |
|
96.1 |
|
|
96.1 |
||
Restricted investment (2) |
|
79.3 |
|
|
79.3 |
||
Net Debt |
$ |
1,297.1 |
|
$ |
1,297.1 |
||
|
|
|
|
||||
Net Debt Ratio (Non GAAP) |
|
|
|
||||
Adjusted EBITDA (3) |
|
|
|
||||
Adjusted EBITDA - last twelve months (LTM) as of December 31, 2023 |
$ |
396.8 |
|
$ |
377.1 |
||
Net debt ratio (Non GAAP) |
3.3x |
|
3.4x |
_______________ | ||||
(1) |
Includes |
|||
(2) |
Our restricted investment is a trust managed in order to secure repayment of the finance lease obligation associated with Performance Materials' |
|||
(3) |
Refer to the Reconciliation of Net Income (GAAP) to Adjusted EBITDA (Non-GAAP) schedule for the reconciliation to the most comparable GAAP financial measure. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218303081/en/
Caroline Monahan
843-740-2068
media@ingevity.com
Investors:
John E. Nypaver, Jr.
843-740-2002
investors@ingevity.com
Source: Ingevity Corporation